kabutan

ONO PHARMACEUTICAL CO., LTD.(4528) Summary

4528
TSE Prime
ONO PHARMACEUTICAL CO., LTD.
2,381.5
JPY
+79.0
(+3.43%)
Feb 2, 3:30 pm JST
15.38
USD
Feb 2, 1:30 am EST
Result
PTS
outside of trading hours
2,382.2
Feb 2, 11:48 pm JST
Summary Chart Historical News Financial Result
PER
16.7
PBR
1.33
Yield
3.36%
Margin Trading Ratio
11.36
Stock Price
Feb 2, 2026
Opening Feb 2, 9:00 am
2,335.0 JPY 15.04 USD
Previous Close Jan 30
2,302.5 JPY 14.96 USD
High Feb 2, 1:20 pm
2,409.0 JPY 15.56 USD
Low Feb 2, 9:15 am
2,293.0 JPY 14.79 USD
Volume
3,476,000
Trading Value
8.22B JPY 0.05B USD
VWAP
2363.91 JPY 15.27 USD
Minimum Trading Value
238,150 JPY 1,538 USD
Market Cap
1.19T JPY 7.71B USD
Number of Trades
9,971
Liquidity & Number of Trades
As of Feb 2, 2026
Liquidity
High
1-Year Average
4,113
1-Year High Oct 9, 2025
12,294
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 64,200 618,500 9.63
Jan 16, 2026 65,500 664,800 10.15
Jan 9, 2026 61,200 713,400 11.66
Dec 26, 2025 65,200 725,700 11.13
Dec 19, 2025 71,400 784,000 10.98
Company Profile
ONO PHARMACEUTICAL CO., LTD. is a mid-tier pharmaceutical company known for its high ratio of in-house developed products, although many are nearing patent expiration. The company is experiencing growth with its new cancer drug "Opdivo".
Sector
Pharmaceuticals
ONO PHARMACEUTICAL CO., LTD. focuses primarily on prescription pharmaceuticals but also produces over-the-counter medications. The company emphasizes research and development, with a strength in innovative in-house products. It operates internationally through subsidiaries engaged in manufacturing, sales, clinical development, and in-licensing/out-licensing activities. The company has sales subsidiaries in Korea and Taiwan, and subsidiaries for clinical development and licensing activities in the United States and the United Kingdom. ONO has achieved significant success with its pioneering cancer immunotherapy drug "Opdivo". The company has also expanded into healthcare-related products, dental supplies, and digital health fields. ONO actively pursues innovation through acquisitions of pharmaceutical startups. The entire group operates under a single business segment of pharmaceuticals.